FATE News and Press, Fate Therapeutics Inc. From 10/29/20

Amgen Inc. (AMGN) is benefiting from high global demand for its product portfolio and generating positive topline results as evident from its recently released financial results. However, the stock has lost nearly 13% in the past month due to no updates on its COVID-19 therapy or vaccine. Fin...

Gilead Sciences (GILD) celebrated the recent FDA approval of its COVID-19 antiviral drug remdesivir. However, many scientists remain skeptical about its effectiveness with mixed evidence on the drug, the stock has been on a downward trajectory since its April highs. Find out if GILD can rebou...

SAN DIEGO, Oct. 15, 2020 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, today announced that five abstracts for the Company&...

Fate Therapeutics has outperformed many of its peers in the often volatile and risky biotechnology industry. Over the past three years, the stock has soared well over 900%. With an earnings yield of -3.75%, from a value perspective, FATE is not attractive. For further detail...

Gainers: [[AKBA]] +8%. [[FATE]] +5%. [[CHMA]] +3.5%. [[UAVS]] +3%. [[ZAGG]] +2%.Losers: [[KLIC]] -5.1%. [[ACRS]] -4.6%. [[LITB]] -2.9%. [[CORR]] -2.6%. [[DPW]] -1.3%. For further details see: CORR, FATE, AKBA and DPW among after-hours movers

Biotechs are one of the most interesting and exciting parts of the market. The sector is breaking out to new highs following a long consolidation period from 2014 to 2020. Four of the most promising stocks are SGEN, ALXN, IMMU, and FATE. Investors should have some allocation to biotech st...

SAN DIEGO, Sept. 30, 2020 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, today announced that management will participate in...

While the market has mainly sold-off this month, four biotech stocks have showed strength in anticipation of successful drug candidates: Arena Pharmaceuticals (ARNA), Fate Therapeutics (FATE), Kura Oncology (KURA), and Stoke Therapeutics (STOK). The biotech sector has received a lot of at...

SAN DIEGO, Sept. 04, 2020 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, today announced its participation in the following upcoming i...

SAN DIEGO, Aug. 19, 2020 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, today announced that Edward Dulac has been appointe...